With over ten years of corporate intellectual property management experience in the fields of ADC (Antibody-Drug Conjugate) and RDC (Radiopharmaceutical Drug Conjugate), she specializes in patent strategy

and lifecycle management for innovative drugs. She has led the development of global patent networks for multiple Class 1 new drugs and is skilled in extending market exclusivity through strategies such as

patent lifecycle planning and patent term extension. She possesses extensive experience in cross-border License-in/License-out IP negotiations, supporting companies in technology introduction and commercial transformation.

Currently serving as the Intellectual Property Director at Yantai Dongcheng Pharmaceutical Group Co., Ltd.and Yantai Lannacheng Biotechnology Co., Ltd., she leads her team in establishing comprehensive intellectual property management systems for pharmaceutical products. She also actively contributes to the formulation of industry standards and promotes the advancement of IP protection practices for innovative RDC drugs.